While being a pharmaceutical treatment for a varied kind of conditions, Hydrocortisone for a cure for prostate cancer has seen extensive use. However, the use of Hydrocortisone for a cure for prostate cancer is always accompanied by a lot of other cancer growth inhibiting chemical.
Hydrocortisone, because of its action from the immune system, is regarded as a moderate anti-prostate cancer agent.
A proposal for the use Ketoconazole plus Hydrocortisone as a cure for prostate cancer was suggested at the Prostate Cancer Research Institute (PCRI) after several lab testing in 2002 that showed miraculous successes in suppressing the growth of cancer. The conclusion had shown remarkable results: 88 percent decrease in pain in all of them, and among these had complete remission demonstrating no cancer manifestation 30 months post-treatment.
Another study involving lower doses of Ketoconazole plus Hydrocortisone still had excellent outcomes. Now the topics were 28 patients with progressive prostate cancer and had previous treatment: castrated levels of testosterone and continuing testicular androgen suppression. Although the Low Dose Ketoconazole and Hydrocortisone as a treatment for prostate cancer (called LDK + HC) remains still inconclusive, 13 of the 28 patients experienced a lowering PSA density amounts, as far as 50 percent.
Ketoconazole wasn’t the sole compound used in junction with Hydrocortisone for a cure for prostate cancer. Large-scale clinical trials between the chemical Suramin has shown similar clinical benefits. In this clinical trial, the investigators have determined that 43% of the patients had also experienced pain reduction that lasted about three quarters of a year. Aside from that, the compound Suramin had shown to be in a position to effectively retard the prostate cancer’s development. The conclusion was obtained when a similarly diagnosed patient getting Hydrocortisone plus another compound is compared to another group taking Hydrocortisone plus Suramin.
Prostate cancer, impacting several millions of Americans, has become a critical aging man’s outbreak. And because some of these cancer diseases are particularly resilient especially androgen-independent strains, it gets the ancient method of anti-androgen withdrawal ineffective. What’s more, there’s no way to determine whether the progression to an androgen-independent state has happened. That’s why secondary hormonal manipulation using Hydrocortisone for a treatment for prostate cancer has been keenly pursued.